Related Experiment Videos
A highly sensitive fluorescent immunoassay based on avidin-labeled nanocrystals
King-Keung Sin1, Cangel Pui-Yee Chan, Ting-Huen Pang
1Department of Chemistry, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.
Analytical and Bioanalytical Chemistry
|January 6, 2006
Summary
Fluorescent nanocrystals labeled with NeutrAvidin significantly enhance immunoassay sensitivity and lower detection limits. This novel approach offers a faster, more sensitive alternative to traditional labeling methods for biomolecule detection.
Area of Science:
- Biochemistry
- Nanotechnology
- Analytical Chemistry
Background:
- Traditional immunoassays often face limitations in sensitivity and detection limits.
- Fluorescent labeling is crucial for enhancing the sensitivity of bioanalytical assays.
- Developing novel labeling strategies is essential for advancing diagnostic capabilities.
Purpose of the Study:
- To develop and evaluate the efficacy of fluorescein diacetate (FDA) nanocrystals as fluorescent labels for immunoassays.
- To improve assay sensitivity and lower the limit of detection compared to existing commercial labeling systems.
- To demonstrate the versatility of NeutrAvidin-coated FDA nanocrystals for detecting various analytes.
Main Methods:
- Synthesized FDA nanocrystals coated with distearoylglycerophosphoethanolamine (DSPE) and PEG(2000)-Amine.
- Adsorbed NeutrAvidin onto the functionalized nanocrystal surface for biomolecule coupling.
- Employed the avidin-biotin technique in an immunoassay for mouse immunoglobulin G detection.
- Compared the performance against traditional sandwich assays and commercial labeling systems (FITC, peroxidase).
Main Results:
- FDA nanocrystals, when hydrolyzed, yield a high concentration of fluorescein molecules (approx. 2.6x10^6 per nanocrystal).
- Immunoassays utilizing FDA nanocrystals demonstrated a 2.5-21 fold lower limit of detection.
- The sensitivity was enhanced by 3.5-30 fold compared to assays using commercial labels.
- The method achieved higher sensitivity and lower detection limits without prolonged incubation times.
Conclusions:
- NeutrAvidin-labeled FDA nanocrystals represent a powerful tool for significantly enhancing immunoassay sensitivity.
- This approach offers a superior alternative to conventional labeling methods, improving detection capabilities.
- The developed nanocrystal labeling strategy is adaptable for diverse bioanalytical applications requiring high sensitivity and low detection limits.